See what’s new.
European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
ORSERDU is based on technology licensed out of the lab of Dr. Donald McDonnell (Pharmacology and Cancer Biology, SOM).
Durham-based Restor3d raises $17 million
restor3d, a Duke spinout from the lab of Prof Ken Gall (MEMS, Pratt), is also a Duke Capital Partners portfolio company.
Aspirion Acquires Infinia ML, an established leader in AI and Machine Learning
Infinia ML is a Duke artificial intelligence start-up spun out of the lab of Professor Lawrence Carin (ECE, Pratt).
Sparta Biomedical Closes an Oversubscribed Convertible Round to Advance its Breakthrough Device
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…
Sparta Biomedical Celebrates Prestigious Recognition in MedTech and Significant Milestone
Sparta Biomedical, a Duke start-up and Duke Capital Partners portfolio company, was founded around technology developed by lead inventor Professor Benjamin Wiley (Chemistry, Trinity), along with Professor Ken Gall (MEMS, Pratt), Professor Matt Becker (Chemistry,…
Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer
Precision BioSciences, a genome editing Duke spin-out, was founded by then-postdocs Jeff Smith and Derek Jantz (Biochemistry, SOM).
Synthetic Antibiotic Could Be Effective Against Drug-Resistant Superbugs
Decades of work by a series of Duke investigators yields new drug, patents and a startup company Valanbio Therapeutics
Clinetic Announces Series A Funding Round Led by Sopris Capital
Clinetic is a medical records Duke start-up founded on technology developed by a team at the Duke Institute for Health Innovation
Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants
Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)